NCT01263613已完成1 期
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Determine feasibility of measuring biomarkers in breast tumors 20 hours after administration of the first dose of paclitaxel chemotherapy.
研究概览
简要总结
The purpose of this study is to determine if the investigators are able to locate and measure certain characteristics in breast cancer tumors that have been treated with paclitaxel that may correlate to how well the cancer will respond to the chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with pathologically demonstrated breast cancer.
- •Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist. Generally this would include:
- •Women with node-positive breast cancer based on ultrasound-guided axillary node biopsy, regardless of hormone or HER2 receptor status.
- •Women with greater than 1 cm breast cancer on imaging (mammogram, ultrasound, breast MRI) who are HER2+ or triple negative (ER-PR-HER2-).
- •Women who are candidates for standard paclitaxel chemotherapy from treating oncologist for any other reason.
- •Patients must not have metastatic disease on staging work-up with chest imaging, CBC, and liver function studies.
- •A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor. A minimum of 5 unstained slides must be available.
- •The primary tumor must be readily able to be biopsied by palpation.
- •The primary tumor must be measurable by an imaging modality prior to treatment. This imaging modality is to be repeated after completion of 4 cycles of paclitaxel and prior to surgery. Such imaging modalities may include ultrasound, CT, mammography, or MRI. MRI will be the preferred imaging modality.
- •Subjects may not have had prior systemic chemotherapy or targeted therapy regimens administered for treatment of their current breast cancer.
- •Age >18 years. Breast cancer is rare in women < 18 years old. The safety of paclitaxel in pediatric population with breast cancer has not been established, therefore these patients are ineligible.
- •Patients must have adequate organ and marrow function
- •Patient must be willing to undergo additional biopsy of breast tumor.
- •Patient must have the ability and willingness to sign a written informed consent document.
排除标准
- •Patients who have had systemic chemotherapies, targeted therapies or radiotherapy for any cancer within 5 years prior to entering the study.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in Cremophor(R) EL (polyoxyethylated castor oil).
- •Patients with known HIV due to concern that chemotherapy may cause further immunosuppression and potential infectious complications.
- •Patients on non-aspirin anti-coagulation (Coumadin, heparins, or clopidogrel) or with documented bleeding disorders will be excluded due to risk of bleeding with biopsy.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, other malignancies requiring therapy or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women are excluded from this study because paclitaxel is a pregnancy category D drug and may cause deleterious effects to the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel, breastfeeding should be discontinued if the mother is enrolled in the trial.
研究组 & 干预措施
Biopsy
Other
biopsy
干预措施: tumor biopsy and blood draw (Procedure)
结局指标
主要结局
Determine feasibility of measuring biomarkers in breast tumors 20 hours after administration of the first dose of paclitaxel chemotherapy.
时间窗: 1 year
次要结局
- Compare biomarkers from tissue samples obtained 20 hours after administration of paclitaxel with tissue obtained at the time of surgery.(1 year)
- Measure drug levels in breast tumors 20 hours after administration of paclitaxel(1 year)
- Determine feasibility of correlating drug levels with biomarkers including mitotic index, aneuploidy, and Ki67(1 year)
- Determine feasibility of correlating pathologic response and clinical response with biomarkers including mitotic index, aneuploidy, and Ki67.(1 year)
- Determine the feasibility of obtaining circulating tumor cells (CTCs) for analysis including evaluation for mitosis.(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Feasibility study of biomarker development for response prediction by large scale DNA mutational analysis of metastatic lesions.metastatic cancermetastatic solid tumors10017991NL-OMON39548niversitair Medisch Centrum Utrecht80
已完成
不适用
Brain Connectivity in Neurodevelopmental Disorders in Response to TreatmentFragile X SyndromeAutism Spectrum DisordersPsychosisNCT01364818University of North Carolina, Chapel Hill25
已完成
不适用
Feasibility study to use new techniques/biomarkers to measure oxidative stress and the influence of vitamin E and C on these parameters in patients suffering from intermittent claudicatioIntermittent claudicationCirculatory SystemPeripheral vascular diseaseISRCTN69086952Máxima Medical Centre (The Netherlands)17
已完成
不适用
A study of cell signalling biomarkers in patients with tuberous sclerosisTuberous sclerosis complex (TSC)Genetic DiseasesTuberous sclerosisISRCTN62388748Aeovian Pharmaceuticals Inc.14
尚未招募
不适用
To calculate new biomarkers and its efficacy of the progresion for non-alcoholic fatty liver disease patients.non-alcoholic fatty liver disease (NAFLD)JPRN-UMIN000014550Shinshu University of Medicine600